Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Simpson

Nurse Practitioner Meridian, MS Nurse Practitioner

NPI 1003334301 CMS profile 11017290

1800 12Th St, Meridian, MS 39301

Open in the dashboard

General payments

$2,732

55 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Simpson of Meridian, MS is reported in the CMS Open Payments database as having received $2,732 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $508 11
2024 General $444 9
2023 General $82 3
2022 General $1,459 19
2021 General $240 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Simpson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Simpson were reported at $508. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Simpson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $240 $135 $40–$426 $132
2022 $1,459 $152 $48–$470 $149
2023 $82 $166 $54–$529 $160
2024 $444 $173 $55–$556 $164
2025 $508 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Spinal Simplicity, LLC $1,439 15 payments
  2. Boston Scientific Corporation $382 9 payments
  3. Abbott Laboratories $364 14 payments
  4. Medtronic, Inc. $188 3 payments
  5. Curonix LLC $108 1 payment
  6. Collegium Pharmaceutical, Inc. $88 5 payments
  7. Relievant Medsystems, Inc. $47 1 payment
  8. Horizon Therapeutics plc $40 3 payments
  9. AbbVie, Inc. $24 1 payment
  10. BIOTRONIK NRO, Inc. $20 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,711 47 payments
  2. Travel and Lodging $1,021 8 payments
Products named General payments · program years 2021–2025
  1. HA MINUTEMAN G3-R $1,439 15 payments
  2. Intracept Pain $183 3 payments
  3. INTELLIS ADAPTIVESTIM $175 2 payments
  4. Proclaim IPG $128 5 payments
  5. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $108 1 payment
  6. PROCLAIM Structural Heart $104 1 payment
  7. Intracept Intracept Access Instruments (Gen 3)_NMOD $69 2 payments
  8. XTAMPZA $64 4 payments
  9. PROCLAIM Neuromodulation $57 4 payments
  10. ETERNA $51 2 payments
  11. Other $277 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

4,862

Median for Nurse Practitioner: 389

Drug cost

$125,834

Median for Nurse Practitioner: $21,885

Branded share of claims

41.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 66 $40,698
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,310 $28,539
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 453 $11,557
Fentanyl Generic 101 $10,170
Gabapentin Generic 922 $5,730
Xtampza Er Oxycodone Myristate Brand 11 $5,611
Buprenorphine Generic 20 $3,229
Lidocaine Generic 31 $3,034
Morphine Sulfate Er Morphine Sulfate Brand 125 $2,907
Pregabalin Generic 227 $2,065

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$179,957

Of which drugs: $3,024

Medicare patients

359

Average age 73

Services billed

2,930

228 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 35%
Ischemic heart disease 28%
Chronic kidney disease 20%
COPD 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 189 $142
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 68 $34

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record